214 related articles for article (PubMed ID: 10639280)
1. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
Hennequin LF; Thomas AP; Johnstone C; Stokes ES; Plé PA; Lohmann JJ; Ogilvie DJ; Dukes M; Wedge SR; Curwen JO; Kendrew J; Lambert-van der Brempt C
J Med Chem; 1999 Dec; 42(26):5369-89. PubMed ID: 10639280
[TBL] [Abstract][Full Text] [Related]
2. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO
J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999
[TBL] [Abstract][Full Text] [Related]
3. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
[TBL] [Abstract][Full Text] [Related]
4. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
6. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
7. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
[TBL] [Abstract][Full Text] [Related]
8. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
9. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Bold G; Altmann KH; Frei J; Lang M; Manley PW; Traxler P; Wietfeld B; Brüggen J; Buchdunger E; Cozens R; Ferrari S; Furet P; Hofmann F; Martiny-Baron G; Mestan J; Rösel J; Sills M; Stover D; Acemoglu F; Boss E; Emmenegger R; Lässer L; Masso E; Roth R; Schlachter C; Vetterli W
J Med Chem; 2000 Jun; 43(12):2310-23. PubMed ID: 10882357
[TBL] [Abstract][Full Text] [Related]
10. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.
Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Curwen JO; Hennequin LF; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF
Cancer Res; 2000 Feb; 60(4):970-5. PubMed ID: 10706112
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
12. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Pandey A; Volkots DL; Seroogy JM; Rose JW; Yu JC; Lambing JL; Hutchaleelaha A; Hollenbach SJ; Abe K; Giese NA; Scarborough RM
J Med Chem; 2002 Aug; 45(17):3772-93. PubMed ID: 12166950
[TBL] [Abstract][Full Text] [Related]
13. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
14. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Sun L; Tran N; Liang C; Tang F; Rice A; Schreck R; Waltz K; Shawver LK; McMahon G; Tang C
J Med Chem; 1999 Dec; 42(25):5120-30. PubMed ID: 10602697
[TBL] [Abstract][Full Text] [Related]
16. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
17. Flk-1 as a target for tumor growth inhibition.
Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
[TBL] [Abstract][Full Text] [Related]
18. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
19. Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
Garofalo A; Goossens L; Six P; Lemoine A; Ravez S; Farce A; Depreux P
Bioorg Med Chem Lett; 2011 Apr; 21(7):2106-12. PubMed ID: 21353546
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
